OPEN END TURBO BULL OPTIONSSCHEIN - ASTRAZENECA | Market Closed - Börse Stuttgart 19:57:06 07/05/2024 BST | ||
| 6.5 EUR | +1.72% |
|
| Current month | +1.25% | ||
| 1 month | +34.30% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ASTRAZENECA PLC
Latest news about ASTRAZENECA PLC
More news
| Date | Price | Change | Volume |
|---|---|---|---|
| 07/05/24 | 6.5 | +1.72% | 0 |
| 06/05/24 | 6.39 | -0.93% | 0 |
| 03/05/24 | 6.45 | -1.53% | 0 |
| 02/05/24 | 6.55 | +2.02% | 0 |
| 30/04/24 | 6.42 | +0.16% | 0 |
Delayed Quote Börse Stuttgart
Last update May 07, 2024 at 07:57 pm
More quotesStatic data
| Product type | Knock-Out without Stop Loss |
|---|---|
| Buy / Sell | CALL |
| Underlying | ASTRAZENECA PLC |
| Issuer | 
UniCredit
|
| WKN | HR778R |
| ISIN | DE000HR778R8 |
| Date issued | 04/05/2021 |
| Strike | 6,532 p |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 2.26 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 7 € |
|---|---|
| Lowest since issue | 2.01 € |
Company Profile
AstraZeneca PLC is one of the world's leading pharmaceutical groups. Net sales break down by source of income as follows:
- product sales (95.6%). Net sales break down by treatment area between oncology (39.2%), cardiovascular, renal and metabolic diseases (24.2%), respiratory and autoimmune diseases (13.9%), and other (22.7%; inflammatory diseases, neurological diseases, gastrointestinal and infectious diseases);
- collaboration revenue (4.4%).
Net sales are distributed geographically as follows: the United Kingdom (7.4%), Europe (21.2%), America (45.3%) and Africa-Asia-Australia (26.1%).
Sector
-
Consensus: AstraZeneca PLC
Sell
Buy
Mean consensus
BUY
Number of Analysts
22
Last Close Price
152
USD
Average target price
165.3
USD
Spread / Average Target
+8.73%
- Stock Market
- Certificates
- Certificat
